Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia”

15 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 15 results

Testing effectiveness (Phase 2)Study completedNCT00045942
What this trial is testing

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Novartis Pharmaceuticals 144
Not applicableNo Longer AvailableNCT03409081
What this trial is testing

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Who this might be right for
Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT04240002
What this trial is testing

Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Astellas Pharma Global Development, Inc. 9
Large-scale testing (Phase 3)Not Yet RecruitingNCT05876832
What this trial is testing

XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Shijiazhuang Yiling Pharmaceutical Co. Ltd 312
Not applicableNo Longer AvailableNCT05219266
What this trial is testing

Managed Access Programs for PKC412, Midostaurin

Who this might be right for
FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid LeukemiaAcute Myeloid LeukemiaAggressive Systemic Mastocytosis+2 more
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT02421939
What this trial is testing

ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Who this might be right for
Leukemia, Acute Myeloid (AML)
Astellas Pharma Global Development, Inc. 371
Testing effectiveness (Phase 2)Active Not RecruitingNCT03793478
What this trial is testing

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 65
Large-scale testing (Phase 3)Study completedNCT03379727
What this trial is testing

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Who this might be right for
Acute Myeloid Leukemia
Novartis Pharmaceuticals 301
Large-scale testing (Phase 3)Study completedNCT02752035
What this trial is testing

ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Global Development, Inc. 183
Not applicableApproved For MarketingNCT03070093
What this trial is testing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Who this might be right for
Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Astellas Pharma Global Development, Inc.
Large-scale testing (Phase 3)Study completedNCT03182244
What this trial is testing

ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Who this might be right for
AML With FLT3 Mutation
Astellas Pharma Inc 276
Not applicableUnknownNCT05596981
What this trial is testing

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAllogeneic Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University 60
Not applicableStudy completedNCT04691648
What this trial is testing

Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Who this might be right for
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Korea, Inc. 33
Not applicableUnknownNCT05596968
What this trial is testing

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAllogeneic Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University 37
Testing effectiveness (Phase 2)Study completedNCT02927262
What this trial is testing

ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Astellas Pharma Global Development, Inc. 98